396129-53-6 | 4-(3-Pyridin-2-yl-1h-pyrazol-4-yl)quinoline

491-35-0    396129-53-6 

[1]JournalofMedicinalChemistry,2003,vol.46,#19,p.3953-3956

2459-07-6    396129-53-6 

[1]JournalofMedicinalChemistry,2003,vol.46,#19,p.3953-3956

7543-22-8    396129-53-6 

[1]JournalofMedicinalChemistry,2003,vol.46,#19,p.3953-3956

(E)-4-Methoxy-1-pyridin-2-yl-2-quinolin-4-yl-but-2-en-1-one 

  396129-53-6 

[1]JournalofMedicinalChemistry,2003,vol.46,p.3953-3956

491-35-0    396129-53-6 

[1]JournalofMedicinalChemistry,2003,vol.46,p.3953-3956

2459-07-6    396129-53-6 

[1]JournalofMedicinalChemistry,2003,vol.46,p.3953-3956

7543-22-8    396129-53-6 

[1]JournalofMedicinalChemistry,2003,vol.46,p.3953-3956

107-13-1    396129-53-6   

3-(3-pyridin-2-yl-4-quinolin-4-yl-pyrazol-1-yl)-propionitrile 

[1]Patent:WO2004/72033,2004,A2.Locationinpatent:Page43

Title: Inhibition of TGFβ type I receptor activity facilitates liver regeneration upon acute CCl4 intoxication in mice.

Journal: Archives of toxicology 20160201

Title: N-Hydroxycinnamide derivatives of osthole inhibit cell migration and invasion by suppressing Smad2 and Akt pathways in human colorectal adenocarcinoma cells.

Journal: Chemico-biological interactions 20140625

Title: Arsenic trioxide induces cardiac fibroblast apoptosis in vitro and in vivo by up-regulating TGF-β1 expression.

Journal: Toxicology letters 20130607

Title: A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.

Journal: The Biochemical journal 20130415

Title: Synthesis and SAR of b-annulated 1,4-dihydropyridines define cardiomyogenic compounds as novel inhibitors of TGFβ signaling.

Journal: Journal of medicinal chemistry 20121126

Title: Arsenic-induced interstitial myocardial fibrosis reveals a new insight into drug-induced long QT syndrome.

Journal: Cardiovascular research 20121001

Title: A new antifibrotic target of Ac-SDKP: inhibition of myofibroblast differentiation in rat lung with silicosis.

Journal: PloS one 20120101

Title: Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity.

Journal: Nature biotechnology 20111101

Title: Isoangustone A suppresses mesangial fibrosis and inflammation in human renal mesangial cells.

Journal: Experimental biology and medicine (Maywood, N.J.) 20110401

Title: Small molecule inhibitor of type I transforming growth factor-β receptor kinase ameliorates the inhibitory milieu in injured brain and promotes regeneration of nigrostriatal dopaminergic axons.

Journal: Journal of neuroscience research 20110301

Title: SFRP1 reduction results in an increased sensitivity to TGF-β signaling.

Journal: BMC cancer 20110101

Title: The transcription factors Snail and Slug activate the transforming growth factor-beta signaling pathway in breast cancer.

Journal: PloS one 20110101

Title: An in vitro model of the inhibition of axon growth in the lesion scar formed after central nervous system injury.

Journal: Molecular and cellular neurosciences 20100201

Title: Comparison of the effects of the kinase inhibitors imatinib, sorafenib, and transforming growth factor-beta receptor inhibitor on extravasation of nanoparticles from neovasculature.

Journal: Cancer science 20090101

Title: Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.

Journal: Journal of medicinal chemistry 20081225

Title: Intervention in growth factor activated signaling pathways by renally targeted kinase inhibitors.

Journal: Journal of controlled release : official journal of the Controlled Release Society 20081218

Title: Optimization of a dihydropyrrolopyrazole series of transforming growth factor-beta type I receptor kinase domain inhibitors: discovery of an orally bioavailable transforming growth factor-beta receptor type I inhibitor as antitumor agent.

Journal: Journal of medicinal chemistry 20080410

Title: Dihydropyrrolopyrazole transforming growth factor-beta type I receptor kinase domain inhibitors: a novel benzimidazole series with selectivity versus transforming growth factor-beta type II receptor kinase and mixed lineage kinase-7.

Journal: Journal of medicinal chemistry 20060323

Title: Synthesis and activity of new aryl- and heteroaryl-substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain.

Journal: Bioorganic & medicinal chemistry letters 20040705

Title: Novel and potent transforming growth factor beta type I receptor kinase domain inhibitor: 7-amino 4-(2-pyridin-2-yl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)-quinolines.

Journal: Bioorganic & medicinal chemistry letters 20040705

Title: Successful shape-based virtual screening: the discovery of a potent inhibitor of the type I TGFbeta receptor kinase (TbetaRI).

Journal: Bioorganic & medicinal chemistry letters 20031215

Title: Synthesis and activity of new aryl- and heteroaryl-substituted pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain.

Journal: Journal of medicinal chemistry 20030911

Title: Peng SB, et al. Kinetic characterization of novel pyrazole TGF-beta receptor I kinase inhibitors and their blockade of the epithelial-mesenchymal transition. Biochemistry, 2005, 44(7), 2293-2304.

Title: Oka M, et al. Inhibition of endogenous TGF-beta signaling enhances lymphangiogenesis. Blood, 2008, 111(9), 4571-4579.

Title: Naka K, et al. TGF-beta-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia. Nature, 2010, 463(7281), 676-680.